Senseonics盘中暴涨，四季度业绩亮眼，推出新款血糖监测系统
周五，Senseonics Holdings股价大幅拉升，截至发稿涨幅超37%。该公司四季度业绩亮眼，且成功推出Eversense 365连续血糖监测（CGM）系统。
Senseonics公布未经审计的第四季度初步收入约为830万美元，2024年全年收入约为2250万美元。与发布前的第三季度相比，第四季度直接面向消费者(DTC)的销售线索翻了一番。12月份新患者出货量约为600例，是该公司历史上最高的月度总数。
该公司强调了2024年的几项关键成就，包括：2024年患者基数比2023年增加56%，达到约6,000名全球患者；获得FDA批准并与其商业合作伙伴Ascensia合作推出Eversense 365 CGM系统。
Eversense 365的推出，可以通过单个植入式传感器监测血糖水平长达365天，在早期就引起了强烈的兴趣。自Eversense 365推出以来，从竞争对手CGM转向Eversense的患者数量增加了49%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10